Hotline for Health Services for Displaced Lebanese 1787
Hotline for the Patient Admission to Hospitals 01/832700
COVID-19 Vaccine Registration Form covax.moph.gov.lb
MoPH Hotline 1214
Are you a new member? Sign up now
 
Let us help you
Read about the latest topics.

Jabak and Najjari Discussed the Cooperation between Lebanon and Egypt in the Exchange of Medicines

 
Minister of Public Health Jamil Jabak received UN Special coordinator for Lebanon Philippe Lazzarini. Both discussed the collaboration between the Ministry of Public Health and all the UN organizations working in Lebanon, such as UNIFIL, UNRWA or UNESCO. Lazzarini reiterated the continuing support to the activities of the Ministry of Public Health and follow-up of the donor countries’ programs that are related to the health care sector, in addition to building a joint collaboration in development projects between Lebanon and the United Nations and working on the establishment of better relationships.
 
The Egypt ambassador Nazih Najjari visited also Minister Jabak and stressed the importance of the economic collaboration between the two countries, in particular in the field of medicines. Najjari hoped that Jabak would review the hospitalization systems related to the Egyptian community in Lebanon and whether it is possible to develop the systems while paying attention to the health conditions of the community.
 
Jabak also met with UNRWA Director General in Lebanon Claudio Cordone who presided over a delegation from the agency. “The meeting discussed the collaboration between both parties to ensure the access of Palestinians in Lebanon to health, medical and hospitalization services they need,” Cordone stated.
 
Jabak received a delegation from the board of pharmacists in Lebanon headed by Ghassan Al Amin. Both discussed the situation of health care sector in Lebanon, in particular the medicines dossier and the ways to reduce their costs. It was agreed to form a joint committee to discuss the means to achieve this goal.
 
Jabak then met with the ambassador of the Association of the Malta knights Henry D’Aragon accompanied by the chargé d’affaires François Abi Saab and the representative of the association at the Ministry Khaled Kaskas. D’Aragon stressed the Association’s commitment to preserve the best relationships with Lebanon, indicating readiness to develop and improve them.
    1
ATC Name B/G Ingredients Dosage Form ↑ Price
A08AB01 XENICAL B Orlistat - 120mg 120mg Capsule 4,036,903 L.L
L01ED01 XALKORI B Crizotinib - 250mg 250mg Capsule 347,644,061 L.L
L01ED01 XALKORI B Crizotinib - 200mg 200mg Capsule 347,644,061 L.L
J01DD15 XEVANEER G Cefdinir - 300mg 300mg Capsule 1,350,562 L.L
L01ED01 XALKORI B Crizotinib - 250mg 250mg Capsule L.L
L02BB04 XTANDI B Enzalutamide - 40mg 40mg Capsule, soft 278,248,572 L.L
D07AC13 XEMADERM G Mometasone furoate - 0.1% 0.1% Cream 335,961 L.L
S01ED51 XOLAMOL G Timolol (maleate) - 5mg/ml, Dorzolamide HCl - 20mg/ml Drops solution 678,640 L.L
S01ED51 XALACOM B Timolol (maleate) - 6.8mg/ml, Latanoprost - 50?g/ml Drops solution 510,660 L.L
S01EE01 XALATAN B Latanoprost - 50mcg/ml 50mcg/ml Drops solution 704,173 L.L
S01EE01 XALAPROST G Latanoprost - 0.005% w/v 0.005% w/v Drops solution 421,967 L.L
R03DX05 XOLAIR BioTech Omalizumab - 150mg 150mg Injectable lyophilised powder for solution+diluent 54,613,625 L.L
B02BD02 XYNTHA BioTech Moroctocog alfa - 500IU 500IU Injectable lyophilised powder for solution+diluent 23,067,288 L.L
B02BD02 XYNTHA BioTech Moroctocog alfa - 500IU 500IU Injectable lyophilised powder for solution+diluent L.L
B02BD02 XYNTHA BioTech Moroctocog alfa - 500IU 500IU Injectable lyophilised powder for solution+diluent L.L
M03AX01 XEOMIN BioTech Clostridium botulinum type A neurotoxin complex - 100 units LD50 100 units LD50 Injectable powder for solution 20,517,541 L.L
M03AX01 XEOMIN BioTech Clostridium botulinum type A neurotoxin complex - 50 units LD50 50 units LD50 Injectable powder for solution 11,920,109 L.L
R03DX05 XOLAIR BioTech Omalizumab - 150mg 150mg Injectable solution L.L
R03DX05 XOLAIR BioTech Omalizumab - 150mg 150mg Injectable solution 37,110,724 L.L
M05BX04 XGEVA BioTech Denosumab - 120mg 120mg Injectable solution 33,545,669 L.L
A10AE56 XULTOPHY BioTech Insulin degludec - 100U/ml, Liraglutide - 3.6mg/ml Injectable solution 13,503,847 L.L
A10AE56 XULTOPHY BioTech Insulin degludec - 100U/ml, Liraglutide - 3.6mg/ml Injectable solution 13,503,847 L.L
J01DD15 XEVANEER G Cefdinir - 125mg/5ml 125mg/5ml Powder for suspension 1,308,903 L.L
J01DD15 XEVANEER G Cefdinir - 125mg/5ml 125mg/5ml Powder for suspension 686,704 L.L
R01AA07 XYLO-COMOD G Xylometazoline HCl - 0.1% 0.1% Solution 499,909 L.L
H02AB06 XILONE FORTE G Prednisolone sodium phosphate - 15mg/5ml 15mg/5ml Solution 413,903 L.L
D04AB01 XYLOCAINE B Lidocaine - 10mg/spray dose 100mg/ml Spray 667,890 L.L
L04AA29 XELJANZ B Tofacitinib - 5mg 5mg Tablet L.L
N05AX12 XALIPRO G Aripiprazole - 10mg 10mg Tablet 2,123,271 L.L
N05AX12 XALIPRO G Aripiprazole - 15mg 15mg Tablet 2,418,917 L.L
    1
Sitemap
© Copyrights reserved to Ministry of Public Health 2026